Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis

Lancet

Volumn 350, Issue 9089, 1997, Pages 1439-1443

  Giroir, Brett P ^a,e   Quint, Peter A ^b   Barton, Phil ^a   Kirsch, Erica A ^a   Kitchen, Louann ^a   Goldstein, Brahm ^c   Nelson, Betty J ^d   Wedel, Nancy I ^d   Carroll, Stephen F ^d   Scannon, Patrick J ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b LEGACY EMANUEL HOSPITAL   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d XOMA Corporation   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BACTERICIDE; CYTOKINE; ENDOTOXIN; INTERLEUKIN 6; RECOMBINANT PROTEIN;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MENINGOCOCCEMIA; MORTALITY; MULTICENTER STUDY; PEDIATRICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031583752     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)06468-4     Document Type: Article

References (32)

1. Cartwright K. Introduction and historical aspects. In: Cartwright K, ed. Meningococcal disease. New York: Wiley, 1995: 1-19.
2. Havens PL, Garland JS, Brook MM, Dewitz BA, Stremski ES, Troshynski TJ. Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987. Pediatr Infect Dis J 1989; 8: 8-11.
3. Kirsch EA, Barton P, Kitchen L, Giroir BP. Pathophysiology, treatment, and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J 1996; 15; 967-79.
4. Brandtzaeg P, Kierulf P, Gaustad P, et al. Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. J Infect Dis 1989; 159: 195-204.
5. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169: 333-38.
6. Brandtzaeg P, Hogåsen K, Kierulf P, Mollnes TE. The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J Infect Dis 1996; 173: 647-55.
7. Suffredini AF, Frinnm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280-87.
8. Weiss J, Elsbach P, Shu C, et al. Human bactericidal/permeability increasing protein and a recombinant NH2-terminal fragment cause killing of serum-resistant gram negative bacteria in whole blood and inhibit tumor necrosis factor release induced by bacteria. J Clin Invest 1992; 90: 1122-30.
9. Betz-Corradin S, Heumann D, Gallay P. Bactericidal/ permeability increasing protein inhibits induction of macrophage nitric oxide production by lipopolysaccharide. J Infect Dis 1994; 169: 105-11.
10. Horwitz AH, Leigh SD, Abrahamson S, et al. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability increasing protein. Protein Expression Purification 1996; 8:28-40.
11. Ooi CE, Weiss J, Elsbach P. A 25-kDa NH2-terminal fragment carries all the antibacterial activities of the human neutrophil 60-kDa bactericidal/permeability increasing protein. J Biol Chem 1987; 262: 14891-94.
12. von der Möhlen MAM, Kimmings AK, Wedel NI, et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis 1995; 172: 144-51.
13. 23) attenuates endotoxin-induced circulatory changes in humans. Circ Shock 1995; 45: 192-206.
14. von der Möhlen MAM, Van Deventer SJH, Levi M, et al. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI-23). Blood 1995; 85: 3437-43.
15. Bauer RJ, White ML, Nelson BJ, et al. A phase I safety and pharmacokinetic study of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in healthy male volunteers. Shock 1996; 5: 91-96.
16. Fiser DH. Assessing the outcomes of pediatric intensive care. J Pediatr 1992; 121: 68-74.
17. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. JAMA 1995; 273; 383-89.
18. Carnall D. Steep rise reported in meningococcal infections. BMJ 1996; 312: 202.
19. Brandtzaeg P. Pathogenesis of meningococcal infections. In: Cartwright K, ed. Meningococcal disease. New York: Wiley, 1995: 71-114.
20. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227-42.
21. Lechner AJ, Lamprech KE, Johanns CA, Matuschak GM. The recombinant 23-kDA N-terminal fragment of bactericidal/permeability-increasing protein (rBPI-23) decreases Escherichia coli-induced mortality and organ injury during immunosuppression-related neutropenia. Shock 1995; 4; 298-306.
22. Ammons WS, Kung A. A recombinant amino terminal fragment of bactericidal/permeability increasing protein prevents hemodynamic responses to endotoxin. Circ Shock 1993; 41: 176-84.
23. Lambert L, Wong P, Carroll S, Scannon P. Recombinant bactericidal/permeability-increasing protein (r-BPI-21) is bactericidal against Neisseria, Haemophilus and Bacteroides species in vitro. In: Abstract book for 36th International Conference on Antimicrobial Agents and Chemotherapy (1996); 141 (abstr).
24. Stoffel MP, Csernok E, Herzberg C, Johnson T, Carroll SF, Gross WL. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 1996; 104: 54-59.
25. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR, CHESS Trial Study Group. T reatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 1-5.
26. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23; 994-1006.
27. Sinclair JF, Skeoch CH, Hallworth D. Prognosis of meningococcal septicaemia. Lancert 1987; ii: 38.
28. Thomson APJ, Sills JA, Hart CA. Validation of the Glasgow meningococcal septicemia prognostic score: a 10-year retrospective survey. Crit Care Med 1991; 19: 26-30.
29. Shah A, Matthew DJ. lasgow meningococcal septicemia prognostic score in meningococcal septicemia. Crit Care Med 1992; 20; 1495.
30. Thomson A, Marzouk O, Sills J, Hart T. Glasgow meningococcal septicemia prognostic score in meningococcal septicemia. Crit Care Med 1992; 20; 1496.
31. van Deuren M, van der Ven-Jongekrijg J, Bartelink AKM, van Dalen R, Sauerwein RW, van der Meer JWM. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 1995; 172: 433-39.
32. McManus MM, Churchwell KB. Coagulopathy as a predictor of outcome in meningococcal sepsis and the systemic inflammatory response syndrome with purpura. Crit Care Med 1993; 21: 706-11.